Literature DB >> 18000133

Use of statins and beta-blockers after acute myocardial infarction according to income and education.

Jeppe N Rasmussen1, Gunnar H Gislason, Søren Rasmussen, Steen Z Abildstrom, Tina K Schramm, Lars Køber, Finn Diderichsen, Merete Osler, Christian Torp-Pedersen, Mette Madsen.   

Abstract

OBJECTIVE: To study the initiation of and long-term refill persistency with statins and beta-blockers after acute myocardial infarction (AMI) according to income and education. DESIGN AND
SETTING: Linkage of individuals through national registers of hospitalisations, drug dispensation, income and education. PARTICIPANTS: 30 078 patients aged 30-74 years surviving first hospitalisation for AMI in Denmark between 1995 and 2001. MAIN OUTCOME MEASURES: Initiation of statin or beta-blocker treatment (out-patient claim of prescriptions within 6 months of discharge) and refill persistency (first break in treatment lasting at least 90 days, and re-initiation of treatment after a break).
RESULTS: When simultaneously estimating the effect of income and education on initiation of treatment, the effect of education attenuated and a clear income gradient remained for both drugs. Among patients aged 30-64 years, high income (adjusted hazard ratio (HR) 1.27; 95% confidence interval (CI) 1.19-1.35) and medium income (HR 1.13; 95% CI 1.06-1.20) was associated with initiation of statin treatment compared with low income. The risk of break in statin treatment was lower for patients with high (HR 0.73; 95% CI 0.66-0.82) and medium (HR 0.82; 95% CI 0.74-0.92) income compared with low income, whereas there was a trend in the opposite direction concerning a break in beta-blocker treatment. There was no gradient in re-initiation of treatment.
CONCLUSION: Patients with low compared with high income less frequently initiated preventive treatment post-AMI, had worse long-term persistency with statins, but tended to have better persistency with beta-blockers. Low income by itself seems not to be associated with poor long-term refill persistency post-AMI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000133      PMCID: PMC2465659          DOI: 10.1136/jech.2006.055525

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  31 in total

1.  A meta-analysis of predictors of positive health practices.

Authors:  Adela Yarcheski; Noreen E Mahon; Thomas J Yarcheski; Barbara L Cannella
Journal:  J Nurs Scholarsh       Date:  2004       Impact factor: 3.176

Review 2.  The assessment of refill compliance using pharmacy records: methods, validity, and applications.

Authors:  J F Steiner; A V Prochazka
Journal:  J Clin Epidemiol       Date:  1997-01       Impact factor: 6.437

3.  The social stratification of aging and health.

Authors:  J S House; J M Lepkowski; A M Kinney; R P Mero; R C Kessler; A R Herzog
Journal:  J Health Soc Behav       Date:  1994-09

4.  Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy.

Authors:  O Mayer; J Simon; J Heidrich; D V Cokkinos; D De Bacquer
Journal:  J Epidemiol Community Health       Date:  2004-01       Impact factor: 3.710

5.  Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment?

Authors:  Li Wei; Robert Flynn; Gordon D Murray; Thomas M MacDonald
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-11       Impact factor: 2.890

Review 6.  Socioeconomic factors and cardiovascular disease: a review of the literature.

Authors:  G A Kaplan; J E Keil
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

7.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.

Authors:  Dennis T Ko; Muhammad Mamdani; David A Alter
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

8.  Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.

Authors:  Jeffrey J Ellis; Steven R Erickson; James G Stevenson; Steven J Bernstein; Renee A Stiles; A Mark Fendrick
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

9.  Pathways between socioeconomic determinants of health.

Authors:  E Lahelma; P Martikainen; M Laaksonen; A Aittomäki
Journal:  J Epidemiol Community Health       Date:  2004-04       Impact factor: 3.710

10.  Statin prescribing in Australia: socioeconomic and sex differences. A cross-sectional study.

Authors:  Nigel P Stocks; Philip Ryan; Heather McElroy; James Allan
Journal:  Med J Aust       Date:  2004-03-01       Impact factor: 7.738

View more
  32 in total

1.  Do immigrants from Turkey, Pakistan and Yugoslavia receive adequate medical treatment with beta-blockers and statins after acute myocardial infarction compared with Danish-born residents? A register-based follow-up study.

Authors:  Nana Folmann Hempler; Finn Diderichsen; Finn Breinholt Larsen; Steen Ladelund; Torben Jørgensen
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

2.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

Review 3.  Predictors of statin adherence.

Authors:  Alexander Mauskop; William B Borden
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

4.  Can We Identify Minority Patients at Risk of Nonadherence to Antiplatelet Medication at the Time of Coronary Stent Placement?

Authors:  Ana M Palacio; Denise C Vidot; Leonardo J Tamariz; Claudia Uribe; Leslie Hazel-Fernandez; Hua Li; Sylvia D Garay; Olveen Carrasquillo
Journal:  J Cardiovasc Nurs       Date:  2017 Nov/Dec       Impact factor: 2.083

Review 5.  Effect of Socioeconomic Status on Propensity to Change Risk Behaviors Following Myocardial Infarction: Implications for Healthy Lifestyle Medicine.

Authors:  Diann E Gaalema; Rebecca J Elliott; Zachary H Morford; Stephen T Higgins; Philip A Ades
Journal:  Prog Cardiovasc Dis       Date:  2017-01-05       Impact factor: 8.194

6.  Family history of cardiovascular disease and influence on statin therapy persistence.

Authors:  Anna Citarella; Helle Kieler; Anders Sundström; Marie Linder; Björn Wettermark; Ingegärd Anveden Berglind; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2014-03-08       Impact factor: 2.953

7.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

8.  Cholesterol treatment with statins: who is left out and who makes it to goal?

Authors:  Peter Franks; Daniel Tancredi; Paul Winters; Kevin Fiscella
Journal:  BMC Health Serv Res       Date:  2010-03-17       Impact factor: 2.655

Review 9.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Authors:  William H Frishman; Linda S Henderson; Mary Ann Lukas
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications 1997- 2006.

Authors:  H Dominguez; T K Schramm; M L Norgaard; S Z Abildstrøm; L Kober; C Jørgensen; T J Guterbaum; H E Poulsen; C Torp-Pedersen; G H Gislason
Journal:  Open Cardiovasc Med J       Date:  2009-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.